Core B- Molecular Core This Core in the proposal consists of three laboratories, which are also OSUCCC Shared Resources. As incorporation of these three Comprehensive Cancer Center Shared Resources as Core B in this proposal, the three laboratories provide the following essential functions for this program: A) Nucleic Acid Analysis, Hansjuerg Alder, Ph. D., Director The Nucleic Acid Shared resource is used daily by all Project leaders and investigators of this program. Since the facility is specialized in RNA/DNA extraction, DNA/RNA synthesis support, DNA sequencing, genotyping, real-time PCR, and imaging, it will be critical to the success of each of the projects. B) Microarray Analysis, Chang-Gong Liu, Ph. D., Director The microarray Shared Resource is a core laboratory providing daily services and support of high throughput mRNA, non-coding RNA (miRNA) gene expression profiling, Single Nucleotide Polymorphism (SNP) genotyping, DNA copy number detection using Comparative Genomic Hybridization (CGH) and RNA/DNA quality check using Agilent bioanalyzer to the OSUCCC cancer research community. In addition, Microarray Shared Resource is going to provide new service of genome-wide sequencing using emerging SOLiD systems for more extensive discoveries of small non-coding RNA like miRNA and Epigenetic studies in cancer research, as well as for extensive ChlPSeq analysis for targets of a variety of proteins. All these above will be key components for the success of this proposal. C) Proteomics, Kari Green-Church, Ph.D., Director The new Proteomics Shared Resource in the Biomedical Research Tower provides complete proteomic support from start to finish using the current state-of-the-art electrophoresis and imaging equipment, robotic sample handlers and mass spectrometers.

Public Health Relevance

(Seeinstructions):

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA129242-03
Application #
8259218
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2011-05-01
Budget End
2012-04-30
Support Year
3
Fiscal Year
2011
Total Cost
$104,778
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Nakanishi, H; Taccioli, C; Palatini, J et al. (2014) Loss of miR-125b-1 contributes to head and neck cancer development by dysregulating TACSTD2 and MAPK pathway. Oncogene 33:702-12
Di Leva, Gianpiero; Garofalo, Michela; Croce, Carlo M (2014) MicroRNAs in cancer. Annu Rev Pathol 9:287-314
Petruk, Svetlana; Black, Kathryn L; Kovermann, Sina K et al. (2013) Stepwise histone modifications are mediated by multiple enzymes that rapidly associate with nascent DNA during replication. Nat Commun 4:2841
Manfè, Valentina; Biskup, Edyta; Willumsgaard, Ayalah et al. (2013) cMyc/miR-125b-5p signalling determines sensitivity to bortezomib in preclinical model of cutaneous T-cell lymphomas. PLoS One 8:e59390
Di Leva, Gianpiero; Piovan, Claudia; Gasparini, Pierluigi et al. (2013) Estrogen mediated-activation of miR-191/425 cluster modulates tumorigenicity of breast cancer cells depending on estrogen receptor status. PLoS Genet 9:e1003311
Carbonell, Albert; Mazo, Alexander; Serras, Florenci et al. (2013) Ash2 acts as an ecdysone receptor coactivator by stabilizing the histone methyltransferase Trr. Mol Biol Cell 24:361-72
Quintavalle, C; Garofalo, M; Zanca, C et al. (2012) miR-221/222 overexpession in human glioblastoma increases invasiveness by targeting the protein phosphate PTP?. Oncogene 31:858-68
Acunzo, M; Visone, R; Romano, G et al. (2012) miR-130a targets MET and induces TRAIL-sensitivity in NSCLC by downregulating miR-221 and 222. Oncogene 31:634-42
Garofalo, M; Quintavalle, C; Romano, G et al. (2012) miR221/222 in cancer: their role in tumor progression and response to therapy. Curr Mol Med 12:27-33
Iorio, Marilena V; Croce, Carlo M (2012) Causes and consequences of microRNA dysregulation. Cancer J 18:215-22

Showing the most recent 10 out of 33 publications